Cargando…
Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2
Antiprogestins have been largely utilized in reproductive medicine, yet their repositioning for oncologic use is rapidly emerging. In this study we investigated the molecular mediators of the anti-ovarian cancer activity of the structurally related antiprogestins RU-38486, ORG-31710 and CDB-2914. We...
Autores principales: | Goyeneche, Alicia A., Seidel, Erin E., Telleria, Carlos M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348464/ https://www.ncbi.nlm.nih.gov/pubmed/21424700 http://dx.doi.org/10.1007/s10637-011-9655-z |
Ejemplares similares
-
Antiprogestins in gynecological diseases
por: Goyeneche, Alicia A, et al.
Publicado: (2015) -
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression
por: Tieszen, Chelsea R, et al.
Publicado: (2011) -
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity
por: Gamarra-Luques, Carlos D, et al.
Publicado: (2014) -
Antiglucocorticoid RU38486 reduces net protein catabolism in experimental acute renal failure
por: Mondry, Adrian
Publicado: (2005) -
New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach
por: Woźniczka, Magdalena, et al.
Publicado: (2021)